By Deena Beasley
June 30 (Reuters) – The chair of the U.S. House Select Committee on China opened national security investigations into whether five drugmakers including Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country’s military capability.
In the letters to Merck and AbbVie dated Monday and first reported by Reuters on Tuesday, Republican Representative John Moolenaar of Michigan asked the drugmakers to provide by July 17 details of due diligence, data protection processes and other standards at their trial sites in China, particularly in the Xinjiang region and at military hospitals.
The committee also sent letters to Eli Lilly, Pfizer and Bristol Myers Squibb.
Shares of Lilly, Pfizer, Merck and Bristol Myers were down nearly 2%, while AbbVie was down 1% in early trading.
Merck said patient safety and ethical integrity are priorities of its clinical research program and it follows all global guidelines. AbbVie declined to comment. Pfizer declined to comment beyond confirming it received the letter.
Lilly said it is reviewing the letter closely. Bristol did not respond to a request for comment.
A spokesperson for China’s embassy in the U.S. in an email said that there is “nothing credible” in the committee’s actions and China opposes moves to politicize trade and tech issues.
CHINA’S BIOTECH RISE, GROWING GOVERNMENT CONCERNS
The letters note that Xinjiang is the epicenter of Beijing’s “genocide” targeting Uyghurs and other ethnic and religious minorities. They say Chinese researchers have documented lapses in securing informed consent from trial participants.
The Uyghur Forced Labor Prevention Act of 2021 does not specifically address clinical trials, but it reflects best practices given the ethical risks of making sure operations do not involve forced labor, the letters said.
“Through a combination of regulatory reforms, state subsidies, and (at best) questionable ethics, China has transformed itself into the cheapest and fastest place in the world to run early-stage human drug trials,” the letters said.
China in recent years has outstripped the U.S. in trial volume. By 2024, the U.S. share of global early drug development programs had dropped to around 37% from 48% in 2015, while China’s share rose to over 32% from 8%, according to one study.
The Merck and AbbVie investigations are the latest sign of growing U.S. government concern over China’s role in the biotech industry.
The National Security Commission on Emerging Biotechnology in a December report warned that “China has systematically built a vertically integrated biotechnology ecosystem that is now in prime position to challenge U.S. leadership.”
Global drugmakers signed a record $138 billion worth of deals in 2025 to license Chinese experimental medicines.
The letters to AbbVie CEO Robert Michael and Merck CEO Robert Davis say that “while there is no evidence” that either company “has engaged in illegal activity or wrongdoing, conducting clinical trials in China… exposes American companies to ethical and security risks.”
The committee said New Jersey-based Merck has sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials in Xinjiang and 40 at medical centers and hospitals affiliated with China’s military.
It said Illinois-based AbbVie has sponsored or collaborated on more than 100 clinical studies in China since 2007, including at least 17 sites in Xinjiang and 16 at military centers.
“Conducting this research at PRC military hospitals puts the cutting-edge, biotechnology intellectual property of American companies at potential risk of being transferred to the Chinese military,” the letters said.
Moolenaar is also sponsoring a bipartisan bill, the Biotech Investment National Security Act, that would amend last year’s Comprehensive Outbound Investment National Security Act to add biotech to a list of screened technologies. The legislation would require outbound U.S. biotechnology licensing deals, joint ventures and equity investments in China to be subject to strict national security review.
The Biosecure Act, signed into law by President Donald Trump late last year, restricts federal agencies’ business dealings with non-U.S. biotechnology companies.
(Reporting by Deena Beasley in Los Angeles, additional reporting by Mariam E Sunny in Bengaluru; Editing by Caroline Humer, Bill Berkrot and Andrea Ricci)
Comments